Skip to main content
SpringerLink
Log in

Wirksamkeit und Sicherheit der transskleralen Anti-VEGF-Eingabe

Efficacy and safety of intravitreal anti-VEGF-therapy

  • Übersichtsarbeit
  • Published:
Spektrum der Augenheilkunde Aims and scope Submit manuscript

Summary

Since the implementation of intravitreal injections using inhibitors of angiogenesis (anti-VEGF), the course of neovascular AMD has improved significantly in the last years. Nowadays a reliable stabilisation of visual acuity is possible, in most cases a vision gain can be achieved. Due to the positive results, frequency of this intervention has increased and will further rise. So attention has to be turned to safety and efficacy of this treatment. This paper tries to give an overview of the latest studies to effects and potential side effects of the three common substances. Although there is still a lack of randomised multicenter-Studies for Avastin® in the moment, clinical studies of thousands of eyes have shown the same safety profile as for Lucentis®. Numerous studies prove Avastin® to be an effective and safe treatment. As intraocular interventions have a potential risk for complications, attention has to be paid to sterile conditions in the operating room and an adaequate injection technique.

Zusammenfassung

Durch die transsklerale intravitreale Medikamenteneingabe von Angiogenese-Inhibitoren (Anti-VEGF) hat sich der Verlauf der feuchten AMD in den letzten Jahren entscheidend verbessert, erstmals kann der Visus zuverlässig stabilisiert und in vielen Fällen sogar verbessert werden. Durch diesen positiven Verlauf hat die Frequenz dieser Eingriffe dramatisch zugenommen und wird auch noch weiter steigen. Um so mehr ist auf die Wirksamkeit und Zuverlässigkeit dieses Eingriffes Augenmerk zu legen. Diese Arbeit versucht, einen Überblick zu rezenten Studien zu allen drei gängigen Substanzen hinsichtlich des Wirk- und Nebenwirkungsprofils zu geben. Auch wenn derzeit noch große, randomisierte Multizenter-Studien für Avastin® fehlen, zeigen die Anwendungsbeobachtungen an tausenden Augen ein ähnlich sicheres Profil wie für Lucentis®. Wie zahlreiche Studien beweisen, handelt es sich um eine sichere und effektive Methode. Da es sich aber prinzipiell um einen intraokularen Eingriff mit entsprechendem Komplikationsrisiko handelt, muss auf sterile Operationsbedingungen und eine adäquate Injektionstechnik größtes Augenmerk gelegt werden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Schmidt-Erfurth U, Kieselbach G, Schönherr U, Wedrich A, Binder S (2005) Empfehlungen zur Vorgehensweise intravitrealer Injektionen. Spektrum Augenheilkd 2: 68–71

    Article  Google Scholar 

  • Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805–2816

    Article  PubMed  CAS  Google Scholar 

  • Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M (2006) Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113: 1508 e1501–1525

    Google Scholar 

  • Hughes MS, Sang DN (2006) Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg Lasers Imaging 37: 446–454

    PubMed  Google Scholar 

  • Pilli S, Kotsolis A, Spaide RF, Slakter J, Freund KB, Sorenson J, Klancnik J, Cooney M (2008) Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 145: 879–882

    Article  PubMed  CAS  Google Scholar 

  • Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N (2005) Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112: 1048–1053

    Article  PubMed  Google Scholar 

  • Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432–1444

    Article  PubMed  CAS  Google Scholar 

  • Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419–1431

    Article  PubMed  CAS  Google Scholar 

  • Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145: 239–248

    Article  PubMed  CAS  Google Scholar 

  • Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 19: 361–372

    PubMed  Google Scholar 

  • Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol DOI S00029394(09)00102-0 [pii]10.1016/j.ajo.2009.01.024

    Google Scholar 

  • Antoszyk AN, Tuomi L, Chung CY, Singh A (2008) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 145: 862–874

    Article  PubMed  CAS  Google Scholar 

  • Silva RM, Ruiz-Moreno JM, Nascimento J, Carneiro A, Rosa P, Barbosaa A, Carvalheira F, Abreu JR, Cunha-Vaz JG (2008) Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 28: 1117–1123

    Article  PubMed  Google Scholar 

  • Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY (2006) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 124: 1532–1542

    Article  PubMed  CAS  Google Scholar 

  • Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, Recchia FM (2008) Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology 115: 1837–1846

    Article  PubMed  Google Scholar 

  • Song JH, Byeon SH, Lee SC, Koh HJ, Kwon OW (2009) Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy. Ophthalmologica 223: 85–92

    Article  PubMed  CAS  Google Scholar 

  • Krebs I, Lie S, Stolba U, Zeiler F, Felke S, Binder S (2008) Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration. Acta Ophthalmol DOI AOS1312 [pii] 10.1111/j.1755-3768.2008.01312.x

  • Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26: 495–511

    Article  PubMed  Google Scholar 

  • Patel PJ, Bunce C, Tufail A (2008) A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin(R) (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design. Trials 9: 56

    Article  PubMed  Google Scholar 

  • Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS (2006) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113: 2002

    Article  PubMed  Google Scholar 

  • Ladewig MS, Ziemssen F, Jaissle G, Helb HM, Scholl HP, Eter N, Bartz-Schmidt KU, Holz FG (2006) Intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmologe 103: 463–470

    Article  PubMed  CAS  Google Scholar 

  • Arias L, Caminal JM, Casas L, Masuet C, Badia MB, Rubio M, Pujol O, Arruga J (2008) A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 92: 1636–1641

    Article  PubMed  CAS  Google Scholar 

  • Furino C, Boscia F, Recchimurzo N, Besozzi G, Cardascia N, Sborgia L, Niro A, Sborgia C (2008) Intravitreal bevacizumab for treatment-naive subfoveal occult choroidal neovascularization in age-related macular degeneration. Acta Ophthalmol 87: 404–407

    PubMed  Google Scholar 

  • Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN (2008) Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 145: 249–256

    Article  PubMed  CAS  Google Scholar 

  • Cleary CA, Jungkim S, Ravikumar K, Kelliher C, Acheson RW, Hickey-Dwyer M (2008) Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye 22: 82–86

    Article  PubMed  CAS  Google Scholar 

  • Lazic R, Gabric N (2007) Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 114: 1179–1185

    Article  PubMed  Google Scholar 

  • Hahn R, Sacu S, Michels S, Varga A, Weigert G, Geitzenauer W, Vecsei-Marlovits P, Schmidt-Erfurth U (2007) Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration. Ophthalmologe 104: 588–593

    Article  PubMed  CAS  Google Scholar 

  • Sacu S, Michels S, Prager F, Weigert G, Dunavoelgyi R, Geitzenauer W, Pruente C, Schmidt-Erfurth U (2009) Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye DOI eye2008423 [pii] 10.1038/eye.2008.423

  • Weigert G, Michels S, Sacu S, Varga A, Prager F, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 92: 356–360

    Article  PubMed  CAS  Google Scholar 

  • Fung AE, Rosenfeld PJ, Reichel E (2006) The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90: 1344–1349

    Article  PubMed  CAS  Google Scholar 

  • Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ (2008) Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246: 81–87

    Article  PubMed  CAS  Google Scholar 

  • Mason JO, 3rd, White MF, Feist RM, Thomley ML, Albert MA, Persaud TO, Yunker JJ, Vail RS (2008) Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 28: 564–567

    Article  PubMed  Google Scholar 

  • Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, Sawa M, Tsujikawa M, Kusaka S, Tano Y (2008) Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 86: 372–376

    Article  PubMed  Google Scholar 

  • Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S (2009) Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 93: 448–451

    Article  PubMed  CAS  Google Scholar 

  • Modarres M, Naseripour M, Falavarjani KG, Nikeghbali A, Hashemi M, Parvaresh MM (2009) Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD. Retina 29: 319–324

    Article  PubMed  Google Scholar 

  • Yip PP, Woo CF, Tang HY, Ho CK (2009) Triple therapy for Neovascular Age-related macular degeneration using single session Photodynamic therapy combined with intravitreal Bevacizumab and Triamcinolone. Br J Ophthalmol DOI bjo.2008.150987 [pii] 10.1136/bjo.2008.150987

  • Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Bahcecioglu H (2008) The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye DOI eye2008360 [pii] 10.1038/eye.2008.360

  • Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou A, Vergados I (2009) Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 29: 313–318

    Article  PubMed  Google Scholar 

  • Scott IU, Flynn HW Jr (2007) Reducing the risk of endophthalmitis following intravitreal injections. Retina 27: 10–12

    Article  PubMed  Google Scholar 

  • Wickremasinghe SS, Michalova K, Gilhotra J, Guymer RH, Harper CA, Wong TY, Qureshi S (2008) Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 115: 1911–1915

    Article  PubMed  Google Scholar 

  • Georgopoulos M, Polak K, Prager F, Prunte C, Schmidt-Erfurth U (2009) Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 93: 457–462

    Article  PubMed  CAS  Google Scholar 

  • Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, Heier JS, Hollands H, Sharma S (2008) Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 28: 1395–1399

    Article  PubMed  Google Scholar 

  • Jonas JB, Spandau UH, Schlichtenbrede F (2008) Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye 22: 590–591

    Article  PubMed  CAS  Google Scholar 

  • Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H (2009) Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye DOI eye20097 [pii] 10.1038/eye.2009.7

  • Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116: 57–65

    Article  PubMed  Google Scholar 

  • D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B (2006) Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113: 992–1001

    Article  PubMed  Google Scholar 

  • Garg S, Brod R, Kim D, Lane RG, Maguire J, Fischer D (2008) Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. Clin Exp Ophthalmol 36: 252–256

    Article  Google Scholar 

  • Chan CK, Meyer CH, Gross JG, Abraham P, Nuthi AS, Kokame GT, Lin SG, Rauser ME, Kaiser PK (2007) Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 27: 541–551

    Article  PubMed  Google Scholar 

  • Ronan SM, Yoganathan P, Chien FY, Corcostegui IA, Blumenkranz MS, Deramo VA, Elner SG, Fastenberg DA, Johnson MW, Lopez M, Mateo C, Moshfeghi DM, Navarro R, Rosenblatt BJ, Sanislo SR, Saxe SJ, Zacks DN (2007) Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Retina 27: 535–540

    Article  PubMed  Google Scholar 

  • Chang LK, Sarraf D (2007) Tears of the retinal pigment epithelium: an old problem in a new era. Retina 27: 523–534

    Article  PubMed  Google Scholar 

  • Smith BT, Kraus CL, Apte RS (2009) Retinal pigment epithelial tears in ranibizumab-treated eyes. Retina 29: 335–339

    Article  PubMed  Google Scholar 

  • Frenkel RE, Mani L, Toler AR, Frenkel MP (2007) Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol 143: 1034–1035

    Article  PubMed  CAS  Google Scholar 

  • Falkenstein IA, Cheng L, Freeman WR (2007) Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina 27: 1044–1047

    Article  PubMed  Google Scholar 

  • Kim JE, Mantravadi AV, Hur EY, Covert DJ (2008) Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 146: 930–934

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Augenabteilung KH Hietzing, Wien, Austria

    P. V. Vécsei-Marlovits

  2. Augenabteilung KA Rudolfstiftung, Wien, Austria

    S. Binder

  3. Wien, Austria

    M. Stur

Authors
  1. P. V. Vécsei-Marlovits
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Binder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Stur
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. V. Vécsei-Marlovits.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vécsei-Marlovits, P., Binder, S. & Stur, M. Wirksamkeit und Sicherheit der transskleralen Anti-VEGF-Eingabe. Spektrum Augenheilkd. 23, 249–255 (2009). https://doi.org/10.1007/s00717-009-0346-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00717-009-0346-5

Keywords

Schlüsselwörter

Search

Navigation